business research Archives - DelveInsight

business research

transthyretin amyloidosis
Notizia

Arming antibiotics with a vaccination-like immune responseHarnessing the ability of the body’s immune system has already well-tried to be effective in treating cancer. Marcos Pires, Ph.D., a Le...



parkinson's
Parkinson’s and tuberculosis shares a common protein that could provide better drugs for both

A group of researchers has recently discovered that an immune mechanism responsible in clearing bacterial infections may also be involved in causing Parkinson's disease. The study has identified th...


Hematopoietic stem cells
Hematopoietic Stem Cell Transplantation

Hematopoietic stem cells (HSCs) are characterized by the ability to self-renew and differentiate into all mature blood lineages. Stromal interactions with soluble and cell-bound cytokines structure...


transthyretin amyloidosis
Phase 1 data of CYC065; Lysogene delays phase 3 study; Genetic disorders Diagnosis; PD-1 resistan...

Positive Phase 1 data supports Cyclacel’s plans for CDK2/9 inhibitor CYC065 Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares. After th...


Signal Transducer and Activator of Transcription
STAT INHIBITORS- Highly active Pipeline

Signal Transducer and Activator of Transcription (STAT ) is a family of cytoplasmic transcription factors comprising of 7 members-STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6. The STAT fac...


Chronic inflammatory demyelinating polyneuropathy therapies are required with novel and targeted mechanism of action that are more effective, specific, cost effective, and less toxic than existing available treatments.
Chronic Inflammatory Demyelinating Polyneuropathy – lack of Effective treatment

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder which is described as the inflammation of nerve roots and peripheral nerves and destruction of the fatty pro...


Default Blog Image
Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs

Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs After a rough journey in 2017, the road seems clear for French CAR-T specialist Cellectis, which has recently closed ...


Default Blog Image
Hepatic Encephalopathy- Lack of active pipeline products

Hepatic encephalopathy (HE) can be described as deterioration of brain function occurring due to accumulation of toxic substances in the blood which ultimately reach the brain. People with long-st...


BioGen
Business Cocktail

M&A activity of Sanofi and Bioverative for rare blood diseases Sanofi has strengthened its position in hematology & speciality medicine by acquiring Bioverativ, Biogen hemophilia & bloo...


Editor's Pick
Top Drugs To Watch in HIV (2025)

Human Immunodeficiency Virus or HIV is a species of Lentivirus (genus of retrovirus) th...

An in-depth Assessment of the Top Drugs Launched by Leading Global Companies ...

Progress is driven by innovation. When it comes to developing novel medications and the...

Changing Dynamics of HIV-1 Treatment Market

The HIV-1 treatment market for naïve and experienced patients is evolving consistently....

Which Countries Top the Chart in Global Pharmaceutical Market?

The Pharmaceuticals segment of the Healthcare Industry has a significant market across ...

von Willebrand disease (VWD) – Misdiagnosis Still Prevalent!

Von Willebrand disease is a type of blood disorder that causes the blood to clot improp...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.